Life science consultancy BioVid announced the launch of BioVid Mimetics on October 23, 2026, an AI research platform that provides pharmaceutical teams with synthetic physician audiences.
Platform Details
BioVid stated that BioVid Mimetics is grounded in its proprietary MindSet Modeling program, featuring large-scale surveys of practicing physicians. The platform models how physicians interpret evidence, weigh benefits against risks, and make treatment decisions.
According to BioVid, the platform is available off the shelf or tailored with a client's own primary research, supporting message and concept testing, positioning, drivers and barriers, segmentation, and opportunity assessment.
Validation and Availability
BioVid reported that in its validation work to date, mimetic and human cohorts have shown an 80% to 90% match on content, reasoning, and emotion across thousands of parallel tests.
The platform includes mimetic respondents for hybrid studies, a Mimetic Segments App, and client customization options firewalled from other users.
Key facts and where they come from
- BioVid announced the launch of BioVid Mimetics on October 23, 2026.
BRISTOL, Pa., Oct. 23, 2026 /PRNewswire/ — BioVid, a life science consultancy, today announced the launch of BioVid Mimetics™
- BioVid stated that its validation work showed an 80% to 90% match between mimetic and human cohorts.
In BioVid's validation work to date, mimetic and human cohorts have shown an 80% to 90% match on content, reasoning, and emotion across thousands of parallel tests.
Read the original from Company press releases (PR Newswire) →
